Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 21, 2025 07:00 ET | Source: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases

Monte Rosa Therapeutics Announces First Subjects Dosed in P1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader